1 **Title:** Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges,

- 2 adjacent and distant lung tissues
- **Authors and Institution:** Qikang Hu^{1,2,4#}, Yang Gao^{3,5,6,7#}, Meredith Frank^{8#}, Liyan Ji⁹,
- 4 Muyun Peng^{1,2,4}, Chen Chen^{1,2,4}, Bin Wang^{1,2,4}, Yan Hu^{1,2,4}, Zeyu Wu^{1,2,4}, Jina Li^{1,2,4}, Lu
- 5 Shu^{1,2,4}, Qiongzhi He⁹, Yingqian Zhang⁹, Xuefeng Xia⁹, Jianjun Zhang⁸, Xin Yi^{9*},
- 6 Alexandre Reuben^{8*}, Fenglei Yu^{1,2,4*}
- 1.7 ¹ Department of Thoracic Surgery, The Second Xiangya Hospital of Central South
- 8 University, Changsha, P. R. China
- ² Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The
- 10 Second Xiangya Hospital of Central South University, Changsha, China
- ³ Department of Thoracic Surgery, Xiangya Hospital, Central South University,
- 12 Changsha, P. R. China;
- ⁴Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South
- 14 University, Changsha, China
- ^{5.} Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 16 China;
- 17 $\frac{6}{17}$ Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis &
- 18 Treatment, Changsha, China;
- ⁷. National Clinical Research Center for Geriatric Disorders, Changsha, China.

Spatial heterogeneity of T cell across NSCLC tissues

- 21 Anderson Cancer Center, Houston/United States of America
- ⁹ Geneplus-Beijing Institute, Beijing/China

23 **Abstract**

24 **Background**: A better understanding of the T cells in lung cancer and their distribution 25 across tumor-adjacent lungs and the peripheral blood is needed to improve efficacy and 26 minimize toxicity from immunotherapy to lung cancer patients.

27 **Methods**: Here, we performed CDR3β TCR sequencing of 143 samples from 21 patients 28 with early-stage NSCLC including peripheral blood mononuclear cells, tumor, tumor 29 edges (<1cm from tumor), as well as adjacent lungs 1cm, 2cm, 5cm, and 10cm away 30 from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in 31 patients with NSCLC. PD-L1, CD4 and CD8 expression was assessed by 32 immunohistochemical staining and genomic features were derived by targeted sequencing 33 of 1,021 cancer related genes.

34 **Results**: Our study reveals a decreasing gradient in TIL homology with the tumor-edge, 35 adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T 36 cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in 37 pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression.

38 **Conclusions**: The exclusion in T cells at play across the lungs of patients with NSCLC 39 may be potentially the mechanism for lung cancer occurrence.

40 **Keywords:** T cell repertoire, NSCLC, IHC

Spatial heterogeneity of T cell across NSCLC tissues

41

Spatial heterogeneity of T cell across NSCLC tissues

43 **Introduction**

44 Lung cancer is the leading cause of cancer-related deaths and is expected to claim 45 over 130,000 lives in the US in 2022 alone[1] (https://www.cancer.org/research/cancer-46 facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html). About 85% of 47 lung cancer diagnoses are classified as non-small cell lung cancer (NSCLC)[1, 2]. While 48 treatments for early-stage NSCLC bode decent success rates, 75% of patients present 49 with late-stage diseases at the time of diagnosis, for which survival rates are poor[2, 3]. 50 Immunotherapies, such as immune checkpoint blockade (ICB) or adoptive cell therapy 51 (ACT) using autologous T cells, have led to substantial clinical benefit, yet a majority of 52 patients do not respond to treatment or develop secondary resistance[4, 5]. On the other 53 hand, although it is overall better tolerated than conventional chemotherapy, ICB can lead 54 to serious toxicities, some of which can be lethal. These have prompted exploration into 55 immune-related drivers of suboptimal responses and toxicities to identify biomarkers to 56 stratify patients for more personalized treatments.

57 PD-L1 is a widely used predictive marker. However, application across large patient 58 datasets has resulted in inconsistent predictive power[6]. Tumor mutational burden 59 (TMB) is another biomarker associated with efficacious responses to ICB and adoptive 60 transfer of expanded autologous $CD8⁺$ T cells[7, 8]. NSCLC tumors with higher TMB 61 generally have better clinical responses to ICB, perhaps due to a larger pool of neoantigen 62 targets for $CD8^+$ T cell recognition [6, 9-11].

 $CDS⁺ T cells are critical mediators of anti-tumor responses as multiple groups have$ 64 shown that higher numbers of $CDS⁺$ tumor infiltrating lymphocytes (TIL) are associated 65 with improved outcomes[12, 13]. More specifically, recent work from our group

Spatial heterogeneity of T cell across NSCLC tissues

66 identified intratumor differences in the T cell repertoire as prognostic tools in NSCLC. 67 Multi-region TCR sequencing revealed that greater TCR ITH was associated with greater 68 risk of relapse and higher intratumor ITH in clonality was associated with more 69 aggressive disease progression and greater risk of relapse[4]. Our more recent work 70 demonstrated a high proportion of TCR overlap between the tumor and adjacent healthy 71 lung tissue and greater TCR overlap was associated with worse survival[14]. In these 72 studies, we determined that by analyzing the homology in T cell repertoire between 73 tumors and their adjacent lungs, we could identify T cells more likely to recognize viral 74 antigens (bystander T cells), and that these bystander T cells were associated with worse 75 outcome. However, in our prior studies, we were not able to assess any spatial differences 76 in the T cell repertoire of tumor-adjacent lungs based on proximity to the tumor[14]. 77 Here, we used a step-wise approach to deconstruct the T cell repertoire architecture 78 across 6 regions within NSCLC tumor tissue and the surrounding healthy lung tissue. T 79 cell markers and repertoire metrics were compared across resected tissue from the tumor, 80 tumor edge (<1cm from tumor), and 1, 2, 5, and 10 cm away from the tumor across 21 81 lung adenocarcinoma patients in order to better understand the impact of the tumor on the 82 T cell repertoire across the lungs.

83 **Materials and Methods**

84 *Tissue collection*

85 Tissue samples from a total of 21 patients with primary lung cancer were 86 collected at Second Xiangya Hospital of Central South University from September to 87 December 2018. All patients gave written informed consent. The study was approved by 88 the Ethics Committee of Second Xiangya Hospital Central South University (IRB:

Spatial heterogeneity of T cell across NSCLC tissues

92 *Targeted sequencing*

93 DNA was extracted from FFPE of tumor tissues using Promega Maxwell™ RSC 94 DNA FFPE Kit (Lot: AS1135#847221). Blood DNA was used as control. DNA (0.8-1.0 ⁹⁵μg) was sheared into fragments with a peak of 200-250 bp for library preparation using 96 NEBNext® Ultra™ DNA Library Prep Kit (NEB, Ipswich, MA). The barcoded libraries 97 were captured by a customized panel of 1021 genes as previously described[15]. 98 Sequencing was performed on a GeneSeq2000 (Suzhou GenePlus Clinical Laboratory 99 Co, Suzhou, China) platform. Reads with low-quality (a. read with a half bases with 100 quality ≤ 5 ; b. reads with N base $\geq 5\%$; c. reads with average base quality $\lt 0$) were 101 removed from raw sequencing data. Then clean reads were mapped into hg19 human 102 genome using bwa, and reads were further analyzed through sentieon pipeline. Somatic 103 single nucleotide variations and small indels were called by MuTect2 and TNscope, 104 respectively. Final SNVs and indels were filtered by variant allele frequency $\geq 1\%$.

105 *T cell receptor sequencing*

106 Sequencing for human TCRβ chain complementarities determining region 3 107 (CDR3) was performed as previously described[16]. Briefly, V and J genes of CDR3 108 gDNA were amplified with multi-plex primers. The PCR products were sequenced after 109 fragment selection by Illumina platform with paired-end 100bp. The clean data were 110 obtained by removal of low-quality reads. Paired-end reads were used for MIXCR to map

Spatial heterogeneity of T cell across NSCLC tissues

113 *Immunohistochemistry*

114 Tumor tissue PD-L1 was stained by PD-L1 (SP263) antibody (Roche). 115 Experiments were performed as manufacture's instruction. Positive PD-L1 staining 116 defined as 1) >25% of tumor cells exhibit positive membrane staining 2) immune cells 117 present (ICP) >1% and IC positive >=25% or 3) ICP = 1% and IC⁺ = 100%. The IHC 118 results for PD-L1 were viewed by independent two pathologists and averaged together 119 for analysis. CD4⁻ and CD8⁻ antibodies were provided from Servicebio Inc (Wuhan, 120 China). Immunohistochemistry score of CD4 and CD8 positive staining were quantified 121 by artificial intelligence-assistant IHC scoring system (Servicebio Inc, Wuhan, China).

122 *Statistical analysis*

123 All the statistics and graphs were analyzed by R (v 4.1.0). The Mann-Whitney U 124 test was used to determine the differences of numerous continuous data between groups. 125 Correlation was performed by Spearman coefficiency. Paired t-tests and 2-way ANOVA 126 were used when appropriate. Significant differences were considered if $p < 0.05$.

127 **Results**

128 **Study design and patient cohort**

129 To investigate the spatial T cell composition of the tumor and adjacent lung 130 microenvironments, we enrolled a cohort of 21 patients with primary lung tumors (**Fig.** 131 **1A-B**). Patients had early-stage (stage I-III) NSCLC and underwent lobectomies for

Spatial heterogeneity of T cell across NSCLC tissues

132 curative intent. Targeted sequencing was performed to evaluate the genomic landscape, 133 and revealed a high prevalence of *TP53* mutations (55%, 11/20 patients), *EGFR* 134 mutations (45%, 9/20 patients), and ZFHX3 (20%, 4/20 patients) among others (**Fig. 1C**). 135 No differences in T cell repertoire were observed based on mutational landscape nor 136 smoking status (**Supplementary Fig. 1-2**). Clonality and diversity were compared across 137 all tissues for smokers versus non-smokers with no differences seen between the two 138 groups across all tissue samples (**Supplementary Fig. 2**).

139 **Increasing gradient of CD8+ and PD-L1+ observed in tumor periphery**

Previous studies in NSCLC have demonstrated that greater $CD8⁺$ T cell densities 141 within the tumor and tumor edge are associated with increased overall survival and, 142 conversely, higher CD4+ T cell densities are associated with worsened survival [12, 13]. 143 Accordingly, we assessed changes in CD8+ and CD4+ T cell densities within tumor 144 tissue and peripheral regions by immunohistochemistry. No significant difference in 145 CD8⁺ or CD4⁺ T cell densities was observed between tumor tissue and peripheral regions 146 (Fig. 2A-D). However, the CD8⁺:CD4⁺ ratio was higher in the tumor edge, when 147 compared with the tumor itself, indicating the presence of $CD8⁺$ -rich regions in the tumor 148 periphery (**Fig. 2E**). PD-L1 expression was also measured by immunohistochemistry but 149 revealed no differences between regions. However, overall tumor peripheral regions 150 exhibited higher PD-L1 expression on immune cells when compared to the tumor itself 151 (**Fig. 2F-G**).

152 **Regions of T cell high diversity exhibited lowest clonality and PD-L1 expression**

Spatial heterogeneity of T cell across NSCLC tissues

164 **Dominant T cell populations are better conserved in tumor margins compared to** 165 **inside the tumors**

166 Morisita overlap index (MOI) values were calculated between all available 167 regions for 21 patients. As shown in **Supplementary Fig. 4**, substantial interpatient 168 heterogeneity was observed among samples. As expected, lower amount of overlap was 169 seen between tumor tissue and all other tissues, with a modest overlap only with the 170 tumor edge (**Fig. 3F**) (MOI=0.36). Most patients exhibited the highest overlap between 171 2cm and surrounding regions, namely 5cm, 1cm and the tumor edge (**Fig. 3F**) 172 (MOI=0.56, 0.54, and 0.58 respectively). In general, dominant T cell populations were 173 better conserved between the tumor margins and "hot regions" of increased clonality 174 compared to the tumors (**Fig. 3F**).

175 **High clonality regions are infiltrated by fewer predicted pathogen-specific T cells**

Spatial heterogeneity of T cell across NSCLC tissues

196 **Discussion**

197 Checkpoint blockade immunotherapy reactivates T cells exhibiting a given phenotype at 198 the systemic level, regardless of antigen-specificity[20]. Considering PD-1 is

Spatial heterogeneity of T cell across NSCLC tissues

199 indiscriminately expressed on T cells following antigen exposure, reactivation of these T 200 cells may be suboptimal[21]. Thus, a better understanding of the T cell repertoire in the 201 context of the lungs is needed. Here, we performed TCR sequencing on a series of 202 matched samples from 21 patients with early-stage NSCLC. To assess T cell infiltration 203 across the lungs, we obtained samples from tumors, tumor edges, as well as 1cm, 2cm, 204 5cm, and 10cm stepping away from the tumor in addition to from matched peripheral 205 blood.

206 Our spatial analysis of T cell infiltration allowed us to assess spatial T cell 207 distribution across the lungs. Although tumors and adjacent lungs have previously been 208 compared by us and others, such a dissection of the lung spatial environment and its T 209 cell infiltrate and repertoire has not yet been undertaken[14]. Analysis of the homology in 210 the T cell repertoire between the tumor and adjacent lung regions proved consistent with 211 our prior findings. Indeed, MOI between the tumor and adjacent lung was ~0.28, 212 consistent with a prior study by our group demonstrating a median of ~0.3 between 213 tumors and adjacent lungs[14]. The same could be said for MOI between the tumor and 214 peripheral blood, which was ~ 0.18 in our study and ~ 0.15 in the same prior study[14]. 215 However, an important dimension not captured in our prior study was the inclusion of the 216 tumor edge, which showed the highest homology with the tumor, highlighting the overall 217 decreasing gradient in T cell homology from the tumor edge (MOI=0.36), to adjacent 218 lung (0.28), and peripheral blood (0.18). MOI between tumor and tumor edge was also 219 below what was observed in our prior analysis of intratumor heterogeneity (MOI=0.85), 220 as should be expected[4]. The lower homology between the tumor and all regions of the 221 adjacent lungs is suggestive of the potential presence of immune and T cell exclusion

Spatial heterogeneity of T cell across NSCLC tissues

222 mechanisms within the tumor, which prevent T cell infiltration and could therefore 223 explain the higher homology outside the tumor[22, 23].

224 Our analysis revealed increased T cell diversity and decreased T cell clonality in 225 the tumor compared to the tumor edge and adjacent lungs. This supports prior studies by 226 our group in larger cohorts with a lower spatial resolution[14]. Interestingly, by using 227 GLIPH2.0[17], we demonstrate that regions with the highest clonality also present the 228 lowest number of predicted pathogen-specific TCRs. This lack of predicted pathogen-229 specific TCRs could suggest a higher probability of infiltration with tumor-specific 230 TCRs. Although this could be influenced by the increased diversity in pathogen TCR-rich 231 regions, positive correlation between PD-L1 and T cell clonality may be suggestive of 232 adaptive resistance induced by T cell activation and IFN-γ secretion, further supporting 233 our hypothesis.

234 Our study does present certain limitations. First, despite our ability to reproduce 235 several findings from prior studies, our study suffers from a limited sample size, which 236 may have limited our ability to attain statistical significance in certain settings. However, 237 our analysis of 143 samples provides an unprecedented high-resolution analysis of the T 238 cell repertoire in the lungs of NSCLC patients. Second, our analysis of immune 239 phenotypes was unfortunately limited by a lack of tissue availability and a restriction to 240 formalin-fixed paraffin-embedded tissues, preventing us from performing any deeper 241 phenotyping and/or tying TCR sequence to phenotype as has recently been done by 242 others using single cell approaches[24]. Lastly, our analysis of antigen-specificity via 243 GLIPH2.0 remains predictive based on *in silico* analyses and will need to be validated 244 with fresh samples via functional assays, although these were unfortunately unavailable

Spatial heterogeneity of T cell across NSCLC tissues

251 **Ethics approval and consent to participate**

252 The study was approved by the Ethics Committee of Second Xiangya Hospital Central

253 South University (IRB: 2020084).

254 **Consent for publication**

255 All authors have read and approved the article.

256 **Availability of data and material**

257 The authors declare that the data supporting the findings of this study are available within 258 the paper and its Supplementary materials. All data generated during this study are 259 included in this published article and its supplementary information files. All data in this 260 study are available from the corresponding author with a reasonable request.

261 **Competing interests**

262 AR serves on the scientific advisory board and has received honoraria from Adaptive

263 Biotechnologies. Jianjun Zhang reports that grants from Merck, Johnson and Johnson;

264 adversary/consulting/hornoraria fees from Bristol Myers Squibb, AstraZeneca, Geneplus,

265 Innovent, OrigMed, Roche outside the submitted work.

Spatial heterogeneity of T cell across NSCLC tissues

266 **Funding**

267 This work was supported by the National Natural Science Foundation of China 268 (81972195 to Dr. Fenglei Yu), Hunan Provincial Key Area R&D Program (2019SK2253 269 to Dr. Fenglei Yu), and the National Clinical Key Specialty Construction Project (to Dr. 270 Fenglei Yu). This investigation was also supported by the Natural Science Foundation of 271 Hunan Province (2022JJ30925 to Yang Gao) and the Project Program of National 272 Clinical Research Center for Geriatric Disorders (Xiangya Hospital, Grant No. 273 2021LNJJ17 to Yang Gao)

274 **Authors' contributions**

275 Qikang Hu, Jianjun Zhang, Xuefeng Xia, Xin Yi, Alexandre Reuben and Fenglei Yu: 276 conception and design, acquisition of data, data analysis and interpretation, manuscript 277 drafting, critical revision; statistical analyses. Meredith Frank, Liyan Ji, Qiongzhi He, 278 Yingqian Zhang and Jianjun Zhang: manuscript drafting. Jianjun Zhang,Yin Yi, 279 Alexandre Reuben and Fenglei Yu: conceived of the idea, supervised this project and 280 revised the manuscript. Meredith Frank, Liyan Ji, Qiongzhi He, Yingqian Zhang, 281 Alexandre Reuben, Muyun Peng, Xiaofeng Chen and Xuefeng Xia: acquisition of data, 282 data analysis and interpretation. Qikang Hu, Yang Gao, Meredith Frank, Muyun Peng, 283 Xiaofeng Chen, Liyan Ji: contributed reagents/materials/analysis tools. Fenglei Yu, Yang 284 Gao: obtained funding.

285 **Acknowledgements**

286 We thank SAN VALLEY DIAGNOSTICS and Servicebio Co. for the assistance with 287 IHC experiments.

Spatial heterogeneity of T cell across NSCLC tissues

288 **List of Abbreviations:**

- 289 ACT: adoptive cell therapy
- 290 CDR3: complementarities determining region 3
- 291 ICB: immune checkpoint blockade
- 292 ICP: immune cells present
- 293 IMGT: ImMunoGeneTics
- 294 MOI: Morisita overlap index
- 295 NSCLC: non-small cell lung cancer
- 296 TIL: tumor infiltrating lymphocytes
- 297 TMB: Tumor mutational burden

Spatial heterogeneity of T cell across NSCLC tissues

299 **References**

- 300 1 Al-Shahrabani F, Vallbohmer D, Angenendt S, Knoefel WT Surgical strategies in the
- 301 therapy of non-small cell lung cancer. *World J Clin Oncol* 2014;5:595-603.
- 302 2 Siegel RL, Miller KD, Fuchs HE, Jemal A Cancer Statistics, 2021. *CA Cancer J Clin*
- 303 2021;71:7-33.
- 304 3 Gadgeel SM, Ramalingam SS, Kalemkerian GP Treatment of lung cancer. *Radiol Clin*
- 305 *North Am* 2012;50:961-74.
- 306 4 Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ et al. TCR Repertoire
- 307 Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with
- 308 Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. *Cancer Discov* 309 2017;7:1088-97.
- 310 5 Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S et al. Tumor-infiltrating
- 311 lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nat* 312 *Med* 2021;27:1410-8.
- 313 6 Jiang Z, Zhou Y, Huang J A Combination of Biomarkers Predict Response to Immune
- 314 Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. *Front Immunol* 315 2021;12:813331.
- 316 7 Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F et al. Mutational and
- 317 putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
- 318 *Nat Commun* 2017;8:1738.
- 319 8 Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R The Challenges of Tumor
- 320 Mutational Burden as an Immunotherapy Biomarker. *Cancer Cell* 2021;39:154-73.

Spatial heterogeneity of T cell across NSCLC tissues

- 321 9 Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D et al. Molecular
- 322 Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed
- 323 Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer
- 324 Profiled With Targeted Next-Generation Sequencing. *J Clin Oncol* 2018;36:633-41.
- 325 10 Buttner R, Longshore JW, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau
- 326 E et al. (2019) Implementing TMB measurement in clinical practice: considerations on
- 327 assay requirements. ESMO Open, 2019/02/23 edn. pp. e000442
- 328 11 High TMB Predicts Immunotherapy Benefit. *Cancer Discov* 2018;8:668.
- 329 12 Kim SH, Go SI, Song DH, Park SW, Kim HR, Jang I et al. Prognostic impact of CD8
- 330 and programmed death-ligand 1 expression in patients with resectable non-small cell lung
- 331 cancer. *Br J Cancer* 2019;120:547-54.
- 332 13 Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL et al.
- 333 Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in
- 334 Merkel Cell Carcinoma. *Clin Cancer Res* 2016;22:5553-63.
- 335 14 Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC et al. Comprehensive T
- 336 cell repertoire characterization of non-small cell lung cancer. *Nat Commun* 2020;11:603.
- 337 15 Tian P, Zeng H, Ji L, Ding Z, Ren L, Gao W et al. Lung adenocarcinoma with ERBB2
- 338 exon 20 insertions: Comutations and immunogenomic features related to 339 chemoimmunotherapy. *Lung Cancer* 2021;160:50-8.
- 340 16 Han J, Yu R, Duan J, Li J, Zhao W, Feng G et al. Weighting tumor-specific TCR
- 341 repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung
- 342 cancers. *Sci Adv* 2021;7.

Spatial heterogeneity of T cell across NSCLC tissues

- 343 17 Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM Analyzing the Mycobacterium
- 344 tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-
- 345 wide antigen screening. *Nat Biotechnol* 2020;38:1194-202.
- 346 18 Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW et al. Bystander
- 347 CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates.
- 348 *Nature* 2018;557:575-9.
- 349 19 Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ et al.
- 350 Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.
- 351 *Nat Med* 2019;25:89-94.
- 352 20 Sharma P, Allison JP The future of immune checkpoint therapy. *Science* 2015;348:56- 353 61.
- 354 21 Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E et al. 355 Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. *ESMO* 356 *Open* 2017;2:e000213.
- 357 22 Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C et al.
- 358 Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of
- 359 anti-PD-1 treatment. *Proc Natl Acad Sci U S A* 2018;115:E4041-e50.
- 360 23 Spranger S Mechanisms of tumor escape in the context of the T-cell-inflamed and the
- 361 non-T-cell-inflamed tumor microenvironment. *Int Immunol* 2016;28:383-91.
- 362 24 Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S et al. Temporal single-cell tracing
- 363 reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1
- 364 therapy in lung cancer. *Nat Cancer* 2022;3:108-21.
- 365

Spatial heterogeneity of T cell across NSCLC tissues

366 **Figure**

368 Figure 1 A: Schematic representation of experiment design. B: Tissue samples from a 369 total of 6 regions were analyzed for TCR repertoire metrics across n=21 patients. C: 370 Heatmap of clinical characteristics and tumor mutational data of top 20 mutated genes 371 across n=21 patients.

Spatial heterogeneity of T cell across NSCLC tissues

374 Figure 2A: CD8+ cell density (cells/mm2) measured by IHC across all tissues for n=5 375 patients. B: CD4+ cell density (cells/mm2) measured by IHC across all tissues for n=5 376 patients. C: PD-L1 score measured by IHC across all tissues for n=5 patients. D: Median 377 CD8+: CD4+ cell densities (cells/mm2) across all regions for n=5 patients.

Spatial heterogeneity of T cell across NSCLC tissues

380 Figure 3A: Morisita overlap values were calculated between tumor and normal tissue for 381 n=21 patients. From top to bottom: tumor, tumor edge, 1cm, 2cm, 5cm , 10cm from 382 tumor, peripheral blood, respectively. From left to right: tumor, tumor edge, 1cm, 2cm, 383 5cm, 10cm from tumor, peripheral blood. In most patients, the greatest amount of overlap 384 was seen between normal tissues peripheral to the tumor, namely, the tumor edge, 1cm, 385 2cm, and 5cm. The lowest amount of overlap was seen between tumor tissue and 386 remaining tissues. 3B: Average morisita overlap between regions for n=21 patients. From 387 top to bottom: tumor, tumor edge, 1cm, 2cm, 5cm , 10cm from tumor, peripheral blood, 388 respectively. From left to right: tumor, tumor edge, 1cm, 2cm, 5cm, 10cm from tumor, 389 peripheral blood. 3C: Clonality values for all samples for n=21 patients. 3D: Median 390 clonality across regions for n=17 patients. 3E: Median Shannon index values across 391 regions for n=17 patients. 3F: Clonality vs PD-L1 expression (all tissues combined). 392 Pearson's coefficient was used to analyze the association between clonality and PD-L1 393 expression across all tissues for n=5 patients.3G: Clonality vs PD-L1 expression

Spatial heterogeneity of T cell across NSCLC tissues

394 (stratified by tissues). Pearson's coefficient was used to analyze the association between

396

398 Figure 4A: Percentage of predicted pathogen TCRs across all regions for n=21 patients. 399 4B: Median percentage of predicted pathogen TCRs across all regions for n=21 400 patients.4C: Regional clonality values were plotted against median proportion of 401 predicted pathogen TCRs for all tissues. The solid line represents correlation between 402 clonality and predicted pathogen TCRs. Thin dotted lines represent the 95% confidence 403 interval. 4D: Predicted pathogen TCRs (absolute count) vs. CD4+ cell density (cells/mm2) 404 for tumor tissue. Pearson's coefficient was used to analyze the association between the 405 number of predicted pathogen specific TCRs and CD4+ cell density in tumor tissue for 406 n=5 patients. 4E: Predicted pathogen TCRs (absolute count) vs. clonality for tumor tissue. 407 Pearson's coefficient was used to analyze the association between the number of 408 predicted pathogen TCRs and clonality in tumor tissue for n=5 patients.4F: Predicted 409 pathogen TCRs (absolute count) vs. CD8+ cell density (cells/mm2) for tumor tissue.

Spatial heterogeneity of T cell across NSCLC tissues

- 410 Pearson's coefficient was used to analyze the association between the number of
- 411 predicted pathogen specific TCRs and CD8+ cell density in tumor tissue for n=5
- 412 patients.4G: PD-L1 score vs. proportion of predicted pathogen-specific TCRs. Pearson's
- 413 coefficient was used to analyze the association between PD-L1 score and proportion of
- 414 predicted pathogen specific TCRs in tumor tissue for n=5 patients.